BR112014019116A8 - Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo - Google Patents

Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo

Info

Publication number
BR112014019116A8
BR112014019116A8 BR112014019116A BR112014019116A BR112014019116A8 BR 112014019116 A8 BR112014019116 A8 BR 112014019116A8 BR 112014019116 A BR112014019116 A BR 112014019116A BR 112014019116 A BR112014019116 A BR 112014019116A BR 112014019116 A8 BR112014019116 A8 BR 112014019116A8
Authority
BR
Brazil
Prior art keywords
bispecific
antibody molecules
cells
antibody
kit
Prior art date
Application number
BR112014019116A
Other languages
English (en)
Other versions
BR112014019116B1 (pt
BR112014019116A2 (pt
Inventor
Bourquin Carole
Klein Christian
Sustmann Claudio
Niederfellner Gerhard
Castoldi Raffaella
Kobold Sebastian
Endres Stefan
Original Assignee
Hoffmann La Roche
Univ Muenchen Ludwig Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Univ Muenchen Ludwig Maximilians filed Critical Hoffmann La Roche
Publication of BR112014019116A8 publication Critical patent/BR112014019116A8/pt
Publication of BR112014019116A2 publication Critical patent/BR112014019116A2/pt
Publication of BR112014019116B1 publication Critical patent/BR112014019116B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

KIT, MOLÉCULAS DE ANTICORPO, COMPOSIÇÃO FARMACÊUTICA, MÉTODOS DE TRATAMENTO, USOS, VETOR, CÉLULA HOSPEDEIRA E MÉTODO DE PRODUÇÃO DE UMA MOLÉCULA DE ANTICORPO. A presente invenção refere-se a uma molécula de anticorpo (monoclonal) biespecífico com um primeiro domínio de ligação que se liga a um antígeno em células T CD8+ que não ocorre naturalmente em e/ou sobre células T CD8+, e um segundo domínio de ligação que se liga a um antígeno tumor-específico de ocorrência natural na superfície de uma célula tumoral. As moléculas de anticorpo biespecífico (monoclonal) são particularmente úteis em combinação com as células T CD8+ transduzidas compreendendo um antígeno que não ocorre naturalmente em e/ou sobre células T CD8+ e/ou com um receptor de célula T. A invenção também provê o uso das referidas moléculas de anticorpo (biespecífico) como um medicamento, as moléculas de anticorpo (biespecífico) para uso em um método para o tratamento de doenças específicas, bem como uma composição farmacêutica/medicamento compreendendo as referidas moléculas de anticorpo (biespecífico), em que as referidas moléculas de anticorpo (biespecífico) devem ser administradas em combinação com células T CD8+ transduzidas compreendendo um antígeno que não ocorre naturalmente em e/ou sobre células T CD8+ e/ou um receptor de célula T em um regime de tratamento específico. Outros aspectos da invenção são sequências de ácidos nucleicos codificantes das referidas moléculas de anticorpo biespecífico (monoclonal), vetores, células hospedeiras, métodos para a produção da molécula de anticorpo (biespecífico), bem como um kit que compreende a molécula de anticorpo (biespecífico).
BR112014019116-6A 2012-02-03 2013-01-24 Kit, moléculas de anticorpo e uso de uma molécula de anticorpo BR112014019116B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12153786.4 2012-02-03
EP12153786 2012-02-03
PCT/EP2013/051351 WO2013113615A1 (en) 2012-02-03 2013-01-24 Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine

Publications (3)

Publication Number Publication Date
BR112014019116A8 true BR112014019116A8 (pt) 2017-07-11
BR112014019116A2 BR112014019116A2 (pt) 2018-10-09
BR112014019116B1 BR112014019116B1 (pt) 2024-01-23

Family

ID=47747562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019116-6A BR112014019116B1 (pt) 2012-02-03 2013-01-24 Kit, moléculas de anticorpo e uso de uma molécula de anticorpo

Country Status (11)

Country Link
US (2) US10633451B2 (pt)
EP (1) EP2809682B1 (pt)
JP (2) JP6363021B2 (pt)
KR (1) KR102091297B1 (pt)
CN (1) CN104379601B (pt)
BR (1) BR112014019116B1 (pt)
CA (1) CA2861031C (pt)
HK (1) HK1207094A1 (pt)
MX (1) MX366965B (pt)
RU (1) RU2693264C2 (pt)
WO (1) WO2013113615A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
RU2015117393A (ru) 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
TW202130662A (zh) 2015-01-23 2021-08-16 法商賽諾菲公司 特異性結合ｃｄ３及／或ｃｄ１２３之抗—ｃｄ３抗體，抗—ｃｄ１２３抗體及雙特異性抗體
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
KR102537102B1 (ko) 2015-05-29 2023-05-25 엠피베나 테라퓨틱스, 인크. 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
CN104892765B (zh) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 一种抗CD3抗原和Her‑2抗原的双特异性抗体
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
CN105384826A (zh) * 2015-11-19 2016-03-09 广州熙帝生物科技有限公司 表达嵌合抗原受体的脐血有核细胞及其应用
WO2017123627A1 (en) * 2016-01-11 2017-07-20 Stc Biologics, Inc. Bispecific targeting agents and methods for their preparation
WO2017219974A1 (zh) * 2016-06-22 2017-12-28 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
MX2018015414A (es) * 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.
CN110177571B (zh) * 2016-11-18 2024-05-24 加利福尼亚大学董事会 工程化抗体及其用途
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CR20190431A (es) * 2017-03-27 2019-11-01 Hoffmann La Roche Formatos mejorados de receptor de unión a antígeno
EP3601346A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3601345A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
BR112019024291A2 (pt) * 2017-06-09 2020-07-28 Providence Health & Services-Oregon utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer
CA3071540A1 (en) * 2017-07-31 2019-02-07 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3665197A2 (en) * 2017-08-11 2020-06-17 H. Hoffnabb-La Roche Ag Anti-cd8 antibodies and uses thereof
WO2019175806A1 (en) * 2018-03-13 2019-09-19 Vascular Biogenics Ltd. Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules
GB201815045D0 (en) * 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN113039271A (zh) * 2018-10-02 2021-06-25 田边三菱制药株式会社 靶向黏结蛋白聚糖-1和成纤维细胞生长因子受体的双特异性结合剂
WO2021009383A1 (en) * 2019-07-18 2021-01-21 Lindis Blood Care Gmbh Removal of tumor cells from intraoperative autologous blood salvage by using a trifunctional antibody
EP4210735A1 (en) 2020-09-10 2023-07-19 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 antibodies and methods of use thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN112480266B (zh) * 2020-12-04 2021-07-06 广州熙帝生物科技有限公司 一种嵌合抗原受体、嵌合抗原受体脐血有核细胞及应用
WO2023102119A1 (en) * 2021-12-01 2023-06-08 The Brigham And Women's Hospital, Inc. Multispecific t cell engager polypeptides in combination with t cells for cancer therapy
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
CN114716558B (zh) * 2022-04-12 2023-05-05 骏蓦(北京)生物科技有限公司 一种双特异性抗体及其治疗癌症的应用
CN117624375A (zh) * 2022-08-30 2024-03-01 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
WO2024138144A1 (en) * 2022-12-22 2024-06-27 The Medical College Of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997000957A1 (en) 1995-06-23 1997-01-09 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP1348715A3 (en) * 1998-04-21 2003-11-19 Micromet AG CD19xCD3 specific polypeptides and uses thereof
EP1115427B1 (de) * 1998-09-25 2003-12-03 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
ATE328906T1 (de) * 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
CA2625440C (en) * 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2318434A1 (en) 2008-07-31 2011-05-11 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Her2/neu specific t cell receptors
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
EP2241576A1 (en) * 2009-04-17 2010-10-20 Trion Pharma Gmbh Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
EP3505636A1 (en) 2009-04-27 2019-07-03 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
BR112014026990A2 (pt) * 2012-05-24 2017-07-11 Hoffmann La Roche anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia.
MX2018015414A (es) * 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.

Also Published As

Publication number Publication date
BR112014019116B1 (pt) 2024-01-23
US10633451B2 (en) 2020-04-28
RU2014133703A (ru) 2016-04-10
CA2861031C (en) 2022-10-25
RU2693264C2 (ru) 2019-07-01
MX2014008963A (es) 2015-01-16
JP2018110586A (ja) 2018-07-19
JP2015506954A (ja) 2015-03-05
KR102091297B1 (ko) 2020-03-20
US20200317806A1 (en) 2020-10-08
JP6363021B2 (ja) 2018-07-25
BR112014019116A2 (pt) 2018-10-09
CN104379601A (zh) 2015-02-25
KR20140127845A (ko) 2014-11-04
MX366965B (es) 2019-07-31
CA2861031A1 (en) 2013-08-08
US20150010567A1 (en) 2015-01-08
EP2809682A1 (en) 2014-12-10
US11732052B2 (en) 2023-08-22
WO2013113615A1 (en) 2013-08-08
HK1207094A1 (en) 2016-01-22
EP2809682B1 (en) 2020-04-08
CN104379601B (zh) 2021-04-09
JP6700325B2 (ja) 2020-05-27

Similar Documents

Publication Publication Date Title
BR112014019116A8 (pt) Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo
AR125268A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112013020338A2 (pt) proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
BR112014022932A2 (pt) molécula de ligação, seu uso e seu método de produção, molécula de ácido nucleico, vetor, célula hospedeira, e composição
BR112013031892A2 (pt) anticorpos anti-psgl-1 e seu uso
BR112018077375A2 (pt) kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
ECSP14004893A (es) Moléculas de unión para bcma y cd3
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
AR073775A1 (es) Anticuerpos biespecificos anti-vegf/anti- ang -2
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
AR095374A1 (es) Moléculas de unión para bcma y cd3
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
BR112015005380A2 (pt) anticorpos anti-cd3, moléculas biespecíficas de ligação ao antígeno que se ligam à cd3 e cd20, e usos dos mesmos
BR112014010591A2 (pt) proteína de ligação ao antígeno e seu uso como produto de direcionamento para o tratamento de câncer
BR112015021819A2 (pt) Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19
BR112013031262A2 (pt) "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica".
BR112016013493A2 (pt) molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo
BR122020002402B8 (pt) Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
AR090884A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/01/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.